#15#
Revisiones (todas) *** Reviews (all)
RESPIRATORY TRACT TUMORS
(Conceptos / Keywords: NSCLC; SCLC, Mesotheliomas; Tracheal tumors; Bronchial tumors; etc).
December 2012 - January 2013
El sistema de alerta de literatura biomédica© es un servicio GRATUITO. La literatura ha sido compuesta en base a una patente que permite la indexización y ordenación de los artículos por orden de importancia. Consecuentemente existe un copyright de carácter compilativo (todos los derechos reservados). Este documento sólo contiene artículos escritos en Castellano y/o Inglés. Para mayor información visite el portal de la compañía haciendo un clic en la palabra Enlace/Link
The biomedical literature© alert system is a FREE service. The literature has been arranged according to a patent, which entitles the right to cataloguing and sorting articles by true relevance. Consequently, a compilation copyright exists (all rights reserved). Only articles written in Spanish and/or English are included. For more information please visit the website of the company by clicking on the following Enlace/Link
----------------------------------------------------
[1]
TÍTULO / TITLE: - Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Thorax. 2013 Jan 15. doi: 10.1136/thoraxjnl-2012-202592.
●● Enlace al texto completo (gratuito o de pago) 1136/thoraxjnl-2012-202592
AUTORES / AUTHORS: - Zhang J; Zhang YL; Ma KX; Qu JM
INSTITUCIÓN / INSTITUTION: - Department of Pulmonary Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University, , Shanghai, China.
RESUMEN / SUMMARY: - BACKGROUND: Patients with lung cancer are at high risk of venous thromboembolism (VTE), and VTE predicts a poor prognosis. Anticoagulation therefore might be beneficial for these patients. It is not clear whether anticoagulants could improve survival and other outcomes in patients with lung cancer with no indication for anticoagulation. METHODS: We searched the Web of Science, Medline, EMBASE and Cochrane databases for relevant studies. Two reviewers evaluated the studies and extracted data independently. The primary outcomes were 1-year survival and incidence of VTE. Pooled risk ratios (RR) were calculated using control as a reference group and significance was determined by the Z test. RESULTS: Nine eligible studies with 2185 participants were included. Anticoagulation showed significant improvement in survival at 1 year (RR 1.18, 95% CI 1.06 to 1.32; p=0.004) and at 2 years (RR 1.27, 95% CI 1.04 to 1.56; p=0.02), but not at 6 months. Subgroup analysis showed a survival benefit for patients with small cell lung cancer (SCLC) and those with non-advanced/limited cancer. The incidence of VTE (RR=0.55, 95% CI 0.31 to 0.97; p=0.04) and thromboembolic events (RR=0.48, 95% CI 0.28 to 0.82; p=0.008) was reduced with anticoagulation. Both vitamin K antagonist (VKA) and subcutaneous heparin increased the risk of haemorrhage, but heparin did not increase the incidence of major bleeding. CONCLUSIONS: Anticoagulation showed a survival benefit, especially for those with SCLC and prolonged life expectancy, and reduced the risk of VTE in lung cancer patients with no indication for anticoagulants. Subcutaneous heparin is superior to VKA because of a potentially smaller risk of major bleeding.
----------------------------------------------------
[2]
TÍTULO / TITLE: - Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: A population-based study.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Cancer. 2012 Dec 4. doi: 10.1002/cncr.27899.
●● Enlace al texto completo (gratuito o de pago) 1002/cncr.27899
AUTORES / AUTHORS: - Gomez DR; Liao KP; Giordano S; Nguyen H; Smith BD; Elting LS
INSTITUCIÓN / INSTITUTION: - Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. dgomez@mdanderson.org.
RESUMEN / SUMMARY: - BACKGROUND: Nausea and vomiting (N/V) during chemotherapy can have profound clinical and economic consequences. Effective antiemetic agents are available for prophylaxis, but barriers may prevent their use. For this population-based study, the authors assessed the rates of antiemetic prophylaxis use, and predictors of such use, among patients who were receiving platinum-based chemotherapy for lung cancer between 2001 and 2007. METHODS: The authors searched the Texas Cancer Registry-Medicare-linked database for individuals aged >65 years who received platinum-based chemotherapy within 12 months after a first diagnosis of lung cancer from 2001 to 2007; and all patients had continuous Medicare Part A and Part B coverage for the same period. Adherence to recommended regimens for N/V prophylaxis (established by the National Comprehensive Cancer Network) was scored as a binary variable (adherent vs nonadherent) and was calculated as the percentages of treated patients receiving each recommended agent within 1 day of beginning chemotherapy. Logistic regression with stepwise selection was used to examine whether patient characteristics influenced adherence. RESULTS: Of 4566 selected patients, adherence rates for the receipt of serotonin antagonists (eg, ondansetron) with dexamethasone were 60% to 90% regardless of whether the chemotherapy agent was considered moderately or highly emetogenic. The receipt of substance-P antagonists was much less common (<10%) during any period. On multivariate logistic regression modeling, variables that predicted adherence were older age, white race, higher median income, and concurrent radiation therapy. CONCLUSIONS: Recommended use of antiemetics for prophylaxis, especially substance-P antagonists, during chemotherapy for lung cancer is suboptimal. Factors that were correlated with adherence suggest socioeconomic barriers in the community. Cancer 2012. © 2012 American Cancer Society.
----------------------------------------------------
[3]
TÍTULO / TITLE: - Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: A meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Gene. 2013 Jan 9. pii: S0378-1119(12)01644-7. doi: 10.1016/j.gene.2012.12.085.
●● Enlace al texto completo (gratuito o de pago) 1016/j.gene.2012.12.085
AUTORES / AUTHORS: - Hu C; Wang J; Xu Y; Li X; Chen H; Bunjhoo H; Xiong W; Xu Y; Zhao J
INSTITUCIÓN / INSTITUTION: - Department of Respiratory Diseases, Tongji Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
RESUMEN / SUMMARY: - PURPOSE: Matrix metalloproteinase (MMP) 1, MMP2, MMP3 and MMP9 are important members of the MMP family. Recently, many studies have been carried out on the association between polymorphisms of MMP1-1607 1G/2G, MMP2-735 C/T, MMP2-1306 C/T, MMP3-1171 5A/6A and MMP9-1562 C/T and lung cancer risk. However the results of these studies remained inconclusive due to conflicting results from different case-control studies. To clarify these associations, we conducted a meta-analysis. METHODS: We conducted a comprehensive search in Medline, EMBASE, OVID and Chinese Biomedical Literature Database (date from Jan 2000 to Aug 2012). Overall and subgroup analysis by the ethnicity of study population was carried out. Odds ratio (OR) with 95% confidence interval (95%CI) was used to assess the strength of the association. RESULTS: There were 17 studies involving five polymorphic sites in four MMP genes. For MMP1-1607,increased lung cancer risk was found under dominant model (MMP1-1607 1G/2G: OR=1.14, 95%CI=1.03-1.26, P=0.01), but not in the Caucasian population. For MMP2-1306 C/T, T polymorphism decreased lung cancer risk under dominant and recessive models (dominant, OR=0.63, 95%CI=0.46-0.88, P=0.0006; recessive, OR=0.61, 95%CI=0.38-0.99, P=0.04). For MMP9-1562 C/T, TT genotype decreased this risk under the recessive model (OR=0.38, 95%CI=0.19-0.75, P=0.005), but not in the Asian population. For MMP2-735 C/T and MMP3-1171 5A/6A, there was no association between this polymorphism and lung cancer risk under the dominant and recessive models. CONCLUSIONS: MMP1-1607 1G/2G polymorphism increased lung cancer risk in Asians. It was also found thatMMP2-1306 C/T polymorphism decreased lung cancer risk in Asians, while MMP9-1562 C/T polymorphism decreased lung cancer risk in Caucasians. No significant difference was found in any genotype of MMP2-735 C/T and MMP3-1171 5A/6A. Further studies with larger sample sizes should be carried out.
----------------------------------------------------
[4]
TÍTULO / TITLE: - American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation and Management for High-Risk Patients With Stage I Non-small Cell Lung Cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Chest. 2012 Dec;142(6):1620-35. doi: 10.1378/chest.12-0790.
●● Enlace al texto completo (gratuito o de pago) 1378/chest.12-0790
AUTORES / AUTHORS: - Donington J; Ferguson M; Mazzone P; Handy J Jr; Schuchert M; Fernando H; Loo B; Lanuti M; de Hoyos A; Detterbeck F; Pennathur A; Howington J; Landreneau R; Silvestri G
RESUMEN / SUMMARY: - BACKGROUND: The standard treatment of stage I non-small cell lung cancer (NSCLC) is lobectomy with systematic mediastinal lymph node evaluation. Unfortunately, up to 25% of patients with stage I NSCLC are not candidates for lobectomy because of severe medical comorbidity. METHODS: A panel of experts was convened through the Thoracic Oncology Network of the American College of Chest Physicians and the Workforce on Evidence-Based Surgery of the Society of Thoracic Surgeons. Following a literature review, the panel developed 13 suggestions for evaluation and treatment through iterative discussion and debate until unanimous agreement was achieved. RESULTS: Pretreatment evaluation should focus primarily on measures of cardiopulmonary physiology, as respiratory failure represents the greatest interventional risk. Alternative treatment options to lobectomy for high-risk patients include sublobar resection with or without brachytherapy, stereotactic body radiation therapy, and radiofrequency ablation. Each is associated with decreased procedural morbidity and mortality but increased risk for involved lobe and regional recurrence compared with lobectomy, but direct comparisons between modalities are lacking. CONCLUSIONS: Therapeutic options for the treatment of high-risk patients are evolving quickly. Improved radiographic staging and the diagnosis of smaller and more indolent tumors push the risk-benefit decision toward parenchymal-sparing or nonoperative therapies in high-risk patients. Unbiased assessment of treatment options requires uniform reporting of treatment populations and outcomes in clinical series, which has been lacking to date.
----------------------------------------------------
[5]
TÍTULO / TITLE: - Adjuvant antiviral therapy for recurrent respiratory papillomatosis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Cochrane Database Syst Rev. 2012 Dec 12;12:CD005053. doi: 10.1002/14651858.CD005053.pub4.
●● Enlace al texto completo (gratuito o de pago) 1002/14651858.CD005053.pub4
AUTORES / AUTHORS: - Chadha NK; James A
INSTITUCIÓN / INSTITUTION: - Division of Pediatric Otolaryngology - Head and Neck Surgery, University of British Columbia, Vancouver, Canada. nchadha@cw.bc.ca.
RESUMEN / SUMMARY: - BACKGROUND: This is an update of a Cochrane Review originally published in Issue 4, 2005 of The Cochrane Library and previously updated in 2010.Recurrent respiratory papillomatosis is a condition characterised by benign papillomatous (wart-like) growths in the upper airway. It can affect both adults and children causing airway obstruction and voice change. Treatment usually involves repeated surgical debulking of the papillomata. Several agents have been proposed as adjuvants to surgical debulking, including antivirals, administered systemically or injected into the lesions. OBJECTIVES: To assess the effectiveness of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis in children and adults. SEARCH METHODS: We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; EMBASE; CINAHL; Web of Science; BIOSIS Previews; Cambridge Scientific Abstracts; ICTRP and additional sources for published and unpublished trials. The date of the most recent search was 24 February 2012. SELECTION CRITERIA: Randomised controlled trials. DATA COLLECTION AND ANALYSIS: We identified 143 references from the searches. Forty-three were appropriate for retrieval and assessed for eligibility by the authors. One randomised controlled trial met the inclusion criteria, involving 19 participants. We contacted the authors to obtain additional data to facilitate the review. MAIN RESULTS: The included study was a single-institution, randomised, double-blind, placebo-controlled trial of intralesional cidofovir administered at the time of surgical debulking. Adults (n = 15) and children (n = 4) were included. We judged the study to have a reasonably low risk of bias. After a 12-month trial period, no difference was found between the cidofovir and placebo groups. Both groups showed a significant reduction in disease extent (as assessed at the time of surgery using the Derkay Scoring System), but no significant change in health-related quality of life. AUTHORS’ CONCLUSIONS: There is insufficient evidence to support the efficacy of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis in children or adults. The included randomised controlled trial showed no advantage of intralesional cidofovir over placebo at 12 months. The study was limited by a small sample size and a change in the cidofovir concentration midway through the trial, from 0.3 mg/ml in children and 0.75 mg/ml in adults, to 5 mg/ml in both adults and children. An adequately powered randomised controlled trial of intra-lesional cidofovir, consistently using higher concentrations of cidofovir in comparison with injected placebo, would be required to determine effectiveness convincingly. Future studies must include health-related quality of life and symptom-based outcome measures.
----------------------------------------------------
[6]
TÍTULO / TITLE: - Worldwide overview of the current status of lung cancer diagnosis and treatment.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Arch Pathol Lab Med. 2012 Dec;136(12):1478-81. doi: 10.5858/arpa.2012-0295-SA.
●● Enlace al texto completo (gratuito o de pago) 5858/arpa.2012-0295-SA
AUTORES / AUTHORS: - Bunn PA Jr
INSTITUCIÓN / INSTITUTION: - Division of Medical Oncology, University of Colorado, Aurora, CO 80045, USA. Paul.bunn@ucdenver.edu
RESUMEN / SUMMARY: - Lung cancer is the leading worldwide cause of cancer deaths. Smoking is the dominant cause of lung cancer and smoking cessation is the established method to reduce lung cancer mortality. While lung cancer risk is reduced in former smokers, they have a lifelong increase in risk, compared to never-smokers. Novel chemoprevention strategies, such as oral or inhaled prostacyclin analogs, hold promise for these subjects. Low-dose spiral computed tomography screening reduced lung cancer mortality by 20% in high-risk heavy smokers older than 50 years. However, the high false-positive rate (96%) means that screened patients required controlled follow-up in experienced centers. An increasing percentage of patients with advanced lung cancer have molecular drivers in genes for which oral tyrosine kinase inhibitors have been developed.
----------------------------------------------------
[7]
TÍTULO / TITLE: - Association between CYP2A6 genetic polymorphisms and lung cancer: A meta-analysis of case-control studies.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Environ Mol Mutagen. 2012 Nov 30. doi: 10.1002/em.21751.
●● Enlace al texto completo (gratuito o de pago) 1002/em.21751
AUTORES / AUTHORS: - Liu T; Xie CB; Ma WJ; Chen WQ
INSTITUCIÓN / INSTITUTION: - Guangdong Institute of Public Health, Guangzhou, China; Center for Disease Control and Prevention of Guangdong Province, Guangzhou, China; Department of Biostatistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, China.
RESUMEN / SUMMARY: - Cytochrome P450 2A6 (CYP2A6) is an enzyme responsible for the metabolism of nicotine and some tobacco-specific carcinogens (such as N-nitrosamines). CYP2A6 genetic variations are associated with the activity of the CYP2A6 enzyme, which affects smoking behavior and the rate at which some tobacco-specific carcinogens are metabolized, which in turn determines the incidence of lung cancer. Several studies have investigated the relationship between CYP2A6 genotypes and lung cancer; however, the results are controversial. In this meta-analysis, we searched for all studies on the association between CYP2A6 genotypes and lung cancer indexed in the MEDLINE, PubMed, Embase, China Biological Medicine, and Wanfang databases from January 1, 1966 to August 1, 2011. The pooled odds ratios (ORs) for one CYP2A6 mutant allele and two CYP2A6 mutant alleles, in comparison with the wild-type CYP2A6 gene, were 0.82 [95% confidence interval (CI) = 0.73-0.92] and 0.57 (95% CI = 0.48-0.68), respectively. Furthermore, in two studies of participants who were all smokers, the associations of one CYP2A6 mutant allele and two CYP2A6 mutant alleles with reduced risk of lung cancer were strengthened, and the pooled ORs were 0.71 (95% CI = 0.58-0.87) and 0.47 (95% CI = 0.35-0.62), respectively. However, we did not find statistically significant relationships between CYP2A6 genotypes and lung cancer in studies that included both never smokers and smokers (pooled OR(one CYP2A6 mutant allele) = 0.88, 95% CI = 0.76-1.01; pooled OR(two CYP2A6 mutant alleles) = 0.61, 95% CI = 0.35-1.06). The results of this meta-analysis suggest that the reduced-activity CYP2A6 genotype may decrease the risk of lung cancer in smokers only. Environ. Mol. Mutagen., 2012. © 2012 Wiley Periodicals, Inc.
----------------------------------------------------
[8]
TÍTULO / TITLE: - Lung cancer genotype-based therapy and predictive biomarkers: present and future.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Arch Pathol Lab Med. 2012 Dec;136(12):1482-91. doi: 10.5858/arpa.2012-0508-RA.
●● Enlace al texto completo (gratuito o de pago) 5858/arpa.2012-0508-RA
AUTORES / AUTHORS: - Cagle PT; Allen TC
INSTITUCIÓN / INSTITUTION: - Department of Pathology & Genomic Medicine, The Methodist Hospital, Houston, Texas, USA. pcagle@tmhs.org
RESUMEN / SUMMARY: - CONTEXT: The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. OBJECTIVE: To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. DATA SOURCES: Data were obtained from review of the pertinent peer-reviewed literature. CONCLUSIONS: First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist’s already crucial role in precision medicine of lung cancer.
----------------------------------------------------
[9]
TÍTULO / TITLE: - XRCC3 Thr241Met gene polymorphisms and lung cancer risk: a meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Exp Clin Cancer Res. 2013 Jan 4;32(1):1. doi: 10.1186/1756-9966-32-1.
●● Enlace al texto completo (gratuito o de pago) 1186/1756-9966-32-1
AUTORES / AUTHORS: - Zhan P; Wang Q; Qian Q; Yu LK
INSTITUCIÓN / INSTITUTION: - First Department of Respiratory Medicine, Nanjing Chest Hospital, 215 Guangzhou Road, Nanjing, 210029, China. yulike_nanjing@163.com.
RESUMEN / SUMMARY: - ABSTRACT: Many studies have examined the association between the XRCC3 Thr241Met gene polymorphism and lung cancer risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, a meta-analysis was performed. The PubMed, Embase, Web of Science, and CNKI database was searched for case-control studies published up to July 2012. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated.Ultimately, 17 studies, comprising 4123 lung cancer cases and 5597 controls were included. Overall, for T allele carriers (TC + TT) versus the wild-type homozygotes (CC), the pooled OR was 0.95 (95% CI = 0.87-1.04 P = 0.228 for heterogeneity), for TT versus CC the pooled OR was 0.99 (95% CI = 0.86-1.15 P = 0.315 for heterogeneity). In the stratified analysis by ethnicity, histological types of lung cancer and smoking status, no any significantly risks were found for (C/T + T/T) vs C/C or T/T vs C/C. No publication bias was found by using the funnel plot and Egger’s test.Overall, there is no evidence showing a significant correlation between XRCC3 Thr241Met polymorphism and lung cancer risk stratified analysis by ethnicity, histology and smoking status.
----------------------------------------------------
[10]
TÍTULO / TITLE: - Meta-analysis of microRNA expression in lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Int J Cancer. 2012 Dec 6. doi: 10.1002/ijc.27981.
●● Enlace al texto completo (gratuito o de pago) 1002/ijc.27981
AUTORES / AUTHORS: - Vosa U; Vooder T; Kolde R; Vilo J; Metspalu A; Annilo T
INSTITUCIÓN / INSTITUTION: - Department of Biotechnology, Institute of Molecular and Cell Biology, University of Tartu, Riia 23, 51010 Tartu, Estonia.
RESUMEN / SUMMARY: - The prognostic and diagnostic value of microRNA (miRNA) expression aberrations in lung cancer has been studied intensely in recent years. However, due to the application of different technological platforms and small sample size, the miRNA expression profiling efforts have led to inconsistent results between the studies. We performed a comprehensive meta-analysis of 20 published miRNA expression studies in lung cancer, including a total of 598 tumor and 528 non-cancerous control samples. Using a recently published robust rank aggregation method, we identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205 and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143 and miR-145) miRNAs. We conducted a gene set enrichment analysis to identify pathways that are most strongly affected by altered expression of these miRNAs. We found that meta-signature miRNAs cooperatively target functionally related and biologically relevant genes in signaling and developmental pathways. We have shown that such meta-analysis approach is suitable and effective solution for identification of statistically significant miRNA meta-signature by combining several miRNA expression studies. This method allows the analysis of data produced by different technological platforms that cannot be otherwise directly compared or in the case when raw data are unavailable.
----------------------------------------------------
[11]
TÍTULO / TITLE: - No significant association between the XRCC3 Thr241Met polymorphism and lung cancer risk: a meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Tumour Biol. 2013 Jan 9.
●● Enlace al texto completo (gratuito o de pago) 1007/s13277-012-0619-5
AUTORES / AUTHORS: - Xu YH; Gu LP; Sun YJ; Cheng BJ; Lu S
INSTITUCIÓN / INSTITUTION: - Shanghai Lung Tumor Clinic Medical Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, No. 241 Huaihai West Road, Shanghai, 200030, China.
RESUMEN / SUMMARY: - The development of lung cancer is significantly associated with genetic susceptibility. Findings from previous individual studies regarding the effect of X-ray repair cross-complementing group 3 Thr241Met (XRCC3 Thr241Met) polymorphism on lung cancer risk remained conflicting and inconclusive. Thus, a meta-analysis of previous relevant studies was performed to estimate this effect more precisely and to shed some light on the contradictory findings. The pooled odds ratios (ORs) with the corresponding 95 % confidence intervals (95 % CIs) were calculated to assess the correlation of XRCC3 Thr241Met polymorphism with lung cancer susceptibility. Stratified analysis according to ethnicity and sensitivity analysis was both conducted for further confirmation. Seventeen independent case-control studies involving 12,610 subjects totally were included into this meta-analysis. Overall, meta-analysis of total included studies showed that the XRCC3 Thr241Met polymorphism was not associated with risk of lung cancer in all genetic contrast models (OR(Met allele vs. Thr allele) = 1.01, 95 % CI 0.91-1.13, P (OR) = 0.810; OR(Met/Met vs. Thr/Thr) = 1.16, 95 % CI 0.88-1.54, P (OR) = 0.281; OR(Thr/Met vs. Thr/Thr) = 0.95, 95 % CI 0.86-1.04, P (OR) = 0.240; OR(Met/Met + Thr/Met vs. Thr/Thr) = 0.97, 95 % CI 0.89-1.06, P (OR) = 0.538; OR(Met/Met vs. Thr/Thr + Thr/Met) = 1.18, 95 % CI 0.91-1.52, P (OR) = 0.204). Stratified analyses in Asians and Caucasians showed similar results. Sensitivity analysis confirmed the stability and reliability of the findings. This meta-analysis of all available data did not support any appreciable association between the XRCC3 Thr241Met polymorphism and lung cancer risk in any populations.
----------------------------------------------------
[12]
TÍTULO / TITLE: - Palliative endobronchial brachytherapy for non-small cell lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Cochrane Database Syst Rev. 2012 Dec 12;12:CD004284. doi: 10.1002/14651858.CD004284.pub3.
●● Enlace al texto completo (gratuito o de pago) 1002/14651858.CD004284.pub3
AUTORES / AUTHORS: - Reveiz L; Rueda JR; Cardona AF
INSTITUCIÓN / INSTITUTION: - Research Promotion and Development Team, Health Systems Based on Primary Health Care (HSS), Pan American Health Organization,Washington DC, USA. mmreveiz@hotmail.com.
RESUMEN / SUMMARY: - BACKGROUND: This is an updated version of the original review published in Issue 2, 2008 of The Cochrane Library. Non-small cell lung cancers (NSCLC) constitute about 80% of all lung cancer cases. Although surgery is the only curative treatment of NSCLC, fewer than 20% of tumors can be radically resected. Radiotherapy is one of the main treatment modalities in lung cancer, contributing to both its cure and palliation. Endobronchial brachytherapy (EBB) has been used as one approach to improve local control either alone or in combination with other treatments. OBJECTIVES: To assess the effectiveness of palliative EBB compared with external beam radiation therapy (EBRT) or other alternative endoluminal treatments in controlling thoracic symptoms and increasing survival in patients with advanced NSCLC. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL,The Cochrane Library, Issue 1 2012), MEDLINE (OvidSP) (1966 to January 2012), EMBASE (Ovid) (1974 to January 2012) and other databases as well as reference lists, and we handsearched selected journals and conference proceedings. SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing different regimens of palliative EBB with EBRT or other endobronchial interventions in patients with advanced NSCLC. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and conducted risk of bias assessment. MAIN RESULTS: We included fourteen RCTs involving 953 participants. We included a new study assessing a variety of different fractionation schedules of high dose rate palliative EBB in this update. There were important differences in the doses of radiotherapy investigated, in the patient characteristics and in the outcomes measured. We found trials comparing EBB to EBRT alone, EBB plus EBRT to EBRT alone, EBB plus chemotherapy to EBB alone, EBB to neodymium: yttrium-aluminum-garnet (Nd-YAG) laser and comparisons between various fractionation schedules of high dose rate EBB. From the heterogeneous information obtained from several small RCTs, we concluded that EBRT alone is more effective for palliation of NSCLC symptoms than EBB alone. Our findings did not provide conclusive evidence to recommend EBB plus EBRT to relieve symptoms compared to EBRT alone. Overall, for the primary endpoint of survival there was no evidence of benefit for EBB compared to EBRT and Nd-YAG laser or for the combination of EBB with chemotherapy. Additionally, findings from one trial suggested that twice 7.4 Gy was superior to the four times per week 3.8 Gy schedule for mean time of local control and fatal hemoptysis. No significant differences were found for fatal hemoptysis as an adverse event of EBB. AUTHORS’ CONCLUSIONS: The evidence did not provide conclusive results that EBB plus EBRT improved symptom relief over EBRT alone. We were not able to provide conclusive evidence to recommend EBB with EBRT, EBB in preference to EBRT, chemotherapy or Nd-YAG laser. From heterogeneous information obtained from several small RCTs, we conclude that EBRT alone is more effective for palliation than EBB alone. For patients previously treated by EBRT who are symptomatic from recurrent endobronchial central obstruction, EBB may be considered in selected cases.
----------------------------------------------------
[13]
TÍTULO / TITLE: - Accuracy of sentinel node biopsy in the staging of non-small cell lung carcinomas: Systematic review and meta-analysis of the literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Lung Cancer. 2013 Jan 22. pii: S0169-5002(13)00007-X. doi: 10.1016/j.lungcan.2013.01.001.
●● Enlace al texto completo (gratuito o de pago) 1016/j.lungcan.2013.01.001
AUTORES / AUTHORS: - Taghizadeh Kermani A; Bagheri R; Tehranian S; Shojaee P; Sadeghi R; N Krag D
INSTITUCIÓN / INSTITUTION: - Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
RESUMEN / SUMMARY: - BACKGROUND: Not all patients with non-small cell lung carcinoma (NSCLC) have mediastinal lymph node involvement and development of less invasive methods for evaluating mediastinal lymph nodes is important. Sentinel node biopsy has been used for NSCLC since 1999 to decrease the need for mediastinal lymph node dissection. In this review, we searched the literature in this regard and reported the results in a meta-analysis format. METHODS: Medline, SCOPUS, and ISI web of knowledge were searched using: “(lung AND sentinel)” with no date or language limit. Any study with more than 5 patients and enough information to calculate detection rate and sensitivity was included. RESULTS: Overall 47 and 43 studies (including subgroups) had the criteria for detection rate and sensitivity pooling respectively. Pooled detection rate was 80.6% [76.8-84%] and pooled sensitivity was 87% [83-90%]. Using radiotracers or both radiotracers and dyes had higher detection rate and sensitivity compared to dye alone. Among studies using radiotracers, highest detection rate was in intra-operative peri-tumoral injection group and highest sensitivity was in peri-tumoral pre-operative injection group. Emerging methods of sentinel node surgery including magnetic materials, fluorescent dyes, CT contrast agents, and carbon nano-particles had promising results. CONCLUSIONS: Sentinel node mapping using radiotracers is a feasible technique for mediastinal lymph node staging of N0 NSCLC patients. Alternative methods of sentinel node mapping are promising and warrant further studies.
----------------------------------------------------
[14]
TÍTULO / TITLE: - Differential diagnosis of lung carcinoma with coherent anti-Stokes Raman scattering imaging.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Arch Pathol Lab Med. 2012 Dec;136(12):1502-10. doi: 10.5858/arpa.2012-0238-SA.
●● Enlace al texto completo (gratuito o de pago) 5858/arpa.2012-0238-SA
AUTORES / AUTHORS: - Gao L; Wang Z; Li F; Hammoudi AA; Thrall MJ; Cagle PT; Wong ST
INSTITUCIÓN / INSTITUTION: - Department of Systems Medicine and Bioengineering, The Methodist Hospital Research Institute, Houston, Texas, USA.
RESUMEN / SUMMARY: - Aimed at bridging imaging technology development with cancer diagnosis, this paper first presents the prevailing challenges of lung cancer detection and diagnosis, with an emphasis on imaging techniques. It then elaborates on the working principle of coherent anti-Stokes Raman scattering microscopy, along with a description of pathologic applications to show the effectiveness and potential of this novel technology for lung cancer diagnosis. As a nonlinear optical technique probing intrinsic molecular vibrations, coherent anti-Stokes Raman scattering microscopy offers an unparalleled, label-free strategy for clinical cancer diagnosis and allows differential diagnosis of fresh specimens based on cell morphology information and patterns, without any histology staining. This powerful feature promises a higher biopsy yield for early cancer detection by incorporating a real-time imaging feed with a biopsy needle. In addition, molecularly targeted therapies would also benefit from early access to surgical specimen with high accuracy but minimum tissue consumption, therefore potentially saving specimens for follow-up diagnostic tests. Finally, we also introduce the potential of a coherent anti-Stokes Raman scattering-based endoscopy system to support intraoperative applications at the cellular level.
----------------------------------------------------
[15]
TÍTULO / TITLE: - Association between the NBS1 Glu185Gln polymorphism and lung cancer risk: a systemic review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Mol Biol Rep. 2012 Dec 29.
●● Enlace al texto completo (gratuito o de pago) 1007/s11033-012-2358-5
AUTORES / AUTHORS: - Wang L; Cheng J; Gao J; Wang J; Liu X; Xiong L
INSTITUCIÓN / INSTITUTION: - Department of Respiratory Medicine, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an, 223300, Jiangsu, People’s Republic of China.
RESUMEN / SUMMARY: - Nijmegen Breakage Syndrome protein 1 (NBS1) is one of the most important DNA repair proteins playing important roles in maintaining the genomic stability of NDA. Previous studies regarding the association between NBS1 8360G>C (Glu185Gln) polymorphism and lung cancer reported conflicting results. To derive a more precise estimation of this association, a systemic review and meta-analysis was performed. We performed a meta-analysis using eligible case-control studies to summarize the data on the association between the NBS1 Glu185Gln polymorphism and lung cancer risk. Odds ratios (ORs) with corresponding 95 % confidence intervals (95 %CIs) were pooled to assess the association between NBS1 Glu185Gln polymorphism and lung cancer risk. Six case-control studies with a total of 2,348 lung cancer cases and 2,401 controls without canner were included into the meta-analysis. Overall, there was an association between NBS1 Glu185Gln polymorphism and lung cancer risk under the dominant comparison model (fixed-effects OR( GluGln/GlnGln vs. GluGlu ) = 1.21, 95 % CI 1.07-1.37, P = 0.002, I (2) = 8.1 %). Subgroup analysis by race suggested a significant association between NBS1 Glu185Gln polymorphism and lung cancer risk in Asians (fixed-effects OR( GluGlnGlnGln vs. GluGlu ) = 1.22, 95 % CI 1.06-1.41, P = 0.005) but not in Caucasians (fixed-effects OR( GluGlnGlnGln vs. GluGlu ) = 1.17, 95 % CI 0.91-1.50, P = 0.220). This meta-analysis supports that there is an association between NBS1 Glu185Gln polymorphism and lung cancer risk. More studies are needed to further verify this association.
----------------------------------------------------
[16]
TÍTULO / TITLE: - Penetration of Recommended Procedures for Lung Cancer Staging and Management in the United States Over 10 Years: A Quality Research in Radiation Oncology Survey.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Int J Radiat Oncol Biol Phys. 2012 Dec 27. pii: S0360-3016(12)03685-1. doi: 10.1016/j.ijrobp.2012.10.016.
●● Enlace al texto completo (gratuito o de pago) 1016/j.ijrobp.2012.10.016
AUTORES / AUTHORS: - Komaki R; Khalid N; Langer CJ; Spring Kong FM; Owen JB; Crozier CL; Wilson JF; Wei X; Movsas B
INSTITUCIÓN / INSTITUTION: - University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: rkomaki@mdanderson.org.
RESUMEN / SUMMARY: - PURPOSE: To document the penetration of clinical trial results, practice guidelines, and appropriateness criteria into national practice, we compared the use of components of staging and treatment for lung cancer among patients treated in 2006-2007 with those used in patients treated in 1998-1999. METHODS AND MATERIALS: Patient, staging work-up, and treatment characteristics were extracted from the process survey database of the Quality Research in Radiation Oncology (QRRO), consisting of records of 340 patients with locally advanced non-small cell lung cancer (LA-NSCLC) at 44 institutions and of 144 patients with limited-stage small cell lung cancer (LS-SCLC) at 39 institutions. Data were compared for patients treated in 2006-2007 versus those for patients treated in 1998-1999. RESULTS: Use of all recommended procedures for staging and treatment was more common in 2006-2007. Specifically, disease was staged with brain imaging (magnetic resonance imaging or computed tomography) and whole-body imaging (positron emission tomography or bone scanning) in 66% of patients with LA-NSCLC in 2006-2007 (vs 42% in 1998-1999, P=.0001) and in 84% of patients with LS-SCLC in 2006-2007 (vs 58.3% in 1998-1999, P=.0011). Concurrent chemoradiation was used for 77% of LA-NSCLC patients (vs 45% in 1998-1999, P<.0001) and for 90% of LS-SCLC patients (vs 62.5% in 1998-1999, P<.0001). Use of the recommended radiation dose (59-74 Gy for NSCLC and 60-70 Gy as once-daily therapy for SCLC) did not change appreciably, being 88% for NSCLC in both periods and 51% (2006-2007) versus 43% (1998-1999) for SCLC. Twice-daily radiation for SCLC was used for 21% of patients in 2006-2007 versus 8% in 1998-1999. Finally, 49% of patients with LS-SCLC received prophylactic cranial irradiation (PCI) in 2006-2007 (vs 21% in 1998-1999). CONCLUSIONS: Although adherence to all quality indicators improved over time, brain imaging and recommended radiation doses for stage III NSCLC were used in <90% of cases. Use of full thoracic doses and PCI for LS-SCLC also requires improvement.
----------------------------------------------------
[17]
TÍTULO / TITLE: - Evidence-based role of bevacizumab in non-small cell lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Ann Oncol. 2013 Jan;24(1):6-9. doi: 10.1093/annonc/mds608.
●● Enlace al texto completo (gratuito o de pago) 1093/annonc/mds608
AUTORES / AUTHORS: - Vokes EE; Salgia R; Karrison TG
INSTITUCIÓN / INSTITUTION: - Department of Medicine, The University of Chicago.
----------------------------------------------------
[18]
TÍTULO / TITLE: - Second Italian Consensus Conference on Malignant Pleural Mesothelioma: State of the art and recommendations.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Cancer Treat Rev. 2012 Dec 11. pii: S0305-7372(12)00236-8. doi: 10.1016/j.ctrv.2012.11.004.
●● Enlace al texto completo (gratuito o de pago) 1016/j.ctrv.2012.11.004
AUTORES / AUTHORS: - Pinto C; Novello S; Torri V; Ardizzoni A; Betta PG; Bertazzi PA; Casalini GA; Fava C; Fubini B; Magnani C; Mirabelli D; Papotti M; Ricardi U; Rocco G; Pastorino U; Tassi G; Trodella L; Zompatori M; Scagliotti G
INSTITUCIÓN / INSTITUTION: - Medical Oncology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy. Electronic address: carmine.pinto@aosp.bo.it.
RESUMEN / SUMMARY: - Malignant pleural mesothelioma (MPM) is a relevant public health issue. A large amount of data indicate a relationship between mesothelioma and asbestos exposure. MPM incidence has considerably and constantly increased over the past two decades in industrialized countries and is expected to peak in 2010-2020. In Italy, the standardized incidence rate in 2008 was 3.6 and 1.3 per 100,000 in men and women respectively, with wide differences from one region to another. The approach to this disease remains difficult and complex in terms of pathogenic mechanism, diagnosis, staging and treatment thus an optimal strategy has not yet been clearly defined. The Second Italian Multidisciplinary Consensus Conference on Malignant Pleural Mesothelioma was held in Turin (Italy) on November 24-25, 2011: recommendations on MPM management for public health institutions, clinicians and patients are presented in this report.
----------------------------------------------------
[19]
TÍTULO / TITLE: - Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Curr Opin Oncol. 2012 Dec 20.
●● Enlace al texto completo (gratuito o de pago) 1097/CCO.0b013e32835ca1b0
AUTORES / AUTHORS: - Felip E; Martinez-Marti A; Martinez P; Cedres S; Navarro A
INSTITUCIÓN / INSTITUTION: - Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, España.
RESUMEN / SUMMARY: - PURPOSE OF REVIEW: Approximately 50% of surgically resected early stage lung cancer patients will relapse and die of recurrent disease within 5 years. In order to reduce the risk of relapse and improve survival, efforts have been focused on the use of chemotherapy before or after surgery. The benefit of adjuvant cisplatin-based chemotherapy is widely accepted for patients with resected stage II-IIIA, although its impact on survival is limited. There is, therefore, a need to find other strategies to further improve survival outcomes. RECENT FINDINGS: In recent years, there has been a marked increase in the development of novel therapeutic strategies targeting signaling pathways, such as epidermal growth factor receptor, angiogenesis, and immunotherapy in stage IV nonsmall cell lung cancer. The potential contribution of these strategies in the adjuvant setting is now being analyzed in randomized clinical trials. SUMMARY: At present, the challenge for research in early stage disease is to define subsets of patients who benefit from certain targeting agents and establish how to integrate such agents into the adjuvant setting.
----------------------------------------------------
[20]
TÍTULO / TITLE: - Isolated chest wall implantation of non-small cell lung cancer after fine-needle aspiration: a case report and review of the literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Tumori. 2012 Sep-Oct;98(5):126e-129e. doi: 10.1700/1190.13213.
●● Enlace al texto completo (gratuito o de pago) 1700/1190.13213
AUTORES / AUTHORS: - Scotti V; Di Cataldo V; Falchini M; Meattini I; Livi L; Ugolini D; Comin CE; Mazza E; Franzese C; Biti G
INSTITUCIÓN / INSTITUTION: - Radiation-Oncology Unit, Department of Clinical Physiopathology, University of Florence, Viale Morgagni 85, Florence, Italy. v.scotti@dfc.unifi.it
RESUMEN / SUMMARY: - Percutaneous fine-needle aspiration biopsy (FNAB) is a well-established and useful procedure in the diagnosis of lung squamous cell carcinoma (LSCC). Tumor seeding has been shown to be a potential risk. We report the case and management of a 78-year-old patient affected by LSCC who developed a chest wall metastasis in a straight line from the primary lesion along the FNAB needle track. Although tumor seeding after FNAB is a rare but possible complication, we suggest that careful examination for implantation (with periodical CT scans) should be performed for at least three years after FNAB.
----------------------------------------------------
[21]
TÍTULO / TITLE: - A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: a report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Int J Clin Oncol. 2013 Jan 26.
●● Enlace al texto completo (gratuito o de pago) 1007/s10147-013-0516-y
AUTORES / AUTHORS: - Maruyama R; Ebi N; Kishimoto J; Kato M; Yano T; Nagamatsu Y; Tsukamoto S; Akamine S; Saeki S; Ichinose Y
INSTITUCIÓN / INSTITUTION: - Department of Chest Surgery, Steel Memorial Yawata Hospital, Kitakyushu, Japan, ri-maruyama@omutatenryo-hp.jp.
RESUMEN / SUMMARY: - BACKGROUND: The present study was designed to determine whether adjuvant chemotherapy with S-1 after surgical resection is feasible in elderly patients with non-small cell lung cancer (NSCLC), using a multi-institutional trial. METHODS: From July 2009 to July 2011, 25 patients received the following regimen: 2 weeks of administration and 1 week of withdrawal of S-1 at 50-100 mg/body per day in an outpatient setting. The primary endpoint of this trial was the completion rate of eight cycles. RESULTS: The completion rate of eight cycles was 70.8 % [95 % confidence interval (CI) 52.7-89.0 %]. The perfect completion rate of eight cycles on schedule with full doses without delays was 50 % (95 % CI 30.0-70.0 %). The reasons for incomplete cycles were: patient refusal in four cases, anorexia in two cases and thrombocytopenia in one case. As a consequence of delays and/or dose reductions, the relative dose intensity of S-1 was 76.3 %. CONCLUSIONS: Adjuvant chemotherapy with S-1 at a reduced dose and schedule was therefore found to be a feasible treatment for elderly Japanese patients who had undergone surgical resection for NSCLC (UMIN Clinical Trials Registry number UMIN000002383).
----------------------------------------------------
[22]
TÍTULO / TITLE: - Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Cancer Control. 2013 Jan;20(1):22-31.
AUTORES / AUTHORS: - Hall RD; Gray JE; Chiappori AA
INSTITUCIÓN / INSTITUTION: - Thoracic Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA. Alberto.Chiappori@Moffitt.org.
RESUMEN / SUMMARY: - BACKGROUND: Lung cancer is the most common cause of cancer-related death in the United States, yet traditional chemotherapy fails to provide long-term benefit for many patients. New approaches are needed to improve overall survival beyond the current standard of care. METHODS: This review discusses recent clinical trials using immunotherapy techniques to treat both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and highlights ongoing immunotherapy research efforts at our center. RESULTS: For NSCLC, phase II clinical trials have examined allogeneic vaccines that target either mucin 1 (MUC1), epidermal growth factor or melanoma-associated antigen 3. These vaccines are now undergoing larger phase III trials. An autologous cellular therapy directed against transforming growth factor beta-2 and a recombinant protein with antitumor properties have also shown promise in prolonging survival in NSCLC in phase II trials. The monoclonal antibodies ipilimumab, BMS-936558 (anti-PD-1), and BMS936559 (anti-PD-L1) lead to enhanced T-cell-mediated antitumor effects and have produced objective responses in early-phase clinical trials. Studies for SCLC also exist, such as a novel vaccine therapy targeting p53. CONCLUSIONS: Recent clinical trials in lung cancer demonstrate the potential of immunotherapeutics to increase overall survival in patients with lung cancer compared with the current standard of care.
----------------------------------------------------
[23]
TÍTULO / TITLE: - The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - BMC Cancer. 2012 Dec 5;12:572. doi: 10.1186/1471-2407-12-572.
●● Enlace al texto completo (gratuito o de pago) 1186/1471-2407-12-572
AUTORES / AUTHORS: - Dhillon HM; van der Ploeg HP; Bell ML; Boyer M; Clarke S; Vardy J
INSTITUCIÓN / INSTITUTION: - Centre for Medical Psychology and Evidence-based Decision-making, University of Sydney, Sydney, Australia. janette.vardy@sydney.edu.au.
RESUMEN / SUMMARY: - ABSTRACT: BACKGROUND: People with lung cancer have substantial symptom burden and more unmet needs than the general cancer population. Physical activity (PA) has been shown to positively influence quality of life (QOL), fatigue and daily functioning in the curative treatment of people with breast and colorectal cancers and lung diseases, as well as in palliative settings. A randomised controlled trial (RCT) is needed to determine if lung cancer patients benefit from structured PA intervention. The Physical Activity in Lung Cancer (PAL) trial is designed to evaluate the impact of a 2-month PA intervention on fatigue and QOL in patients with non-resectable lung cancer. Biological mechanisms will also be studied. METHODS/DESIGN: A multi-centre RCT with patients randomised to usual care or a 2-month PA programme, involving supervised PA sessions including a behavioural change component and home-based PA. QOL questionnaires, disease and functional status and body composition will be assessed at baseline, 2, 4 and 6 months follow-up. The primary endpoint is comparative levels of fatigue between the 2 arms. Secondary endpoints include: QOL, functional abilities and physical function. Exploratory endpoints include: anxiety, depression, distress, dyspnoea, PA behaviour, fitness, hospitalisations, survival, cytokines and insulin-like growth factor levels. DISCUSSION: This study will provide high-level evidence of the effect of PA programmes on cancer-related fatigue and QOL in patients with advanced lung cancer. If positive, the study has the potential to change care for people with cancer using a simple, inexpensive intervention to improve their QOL and help them maintain independent function for as long as possible. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry No. ACTRN12609000971235.
----------------------------------------------------
[24]
TÍTULO / TITLE: - Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Exp Ther Med. 2012 Nov;4(5):849-858. Epub 2012 Aug 31.
●● Enlace al texto completo (gratuito o de pago) 3892/etm.2012.690
AUTORES / AUTHORS: - Zhang J; Zhang W; Huang S; Li H; Li Y; Chen H; Wu W; Zhou W; Wang C; Liao H; Gu L
INSTITUCIÓN / INSTITUTION: - Thoracic Surgery Department and Clinical Research Center for Thoracic Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, P.R. China.
RESUMEN / SUMMARY: - The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence-based methodology. Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 patients as maintenance treatment, while the remaining patients received a placebo or observation only. The meta-analysis was performed using Reviewer Manager Version 5.12 software. Compared with the control group, maintenance erlotinib improved progression-free survival (PFS) and overall survival (OS) with moderate heterogeneity. Results from the random effects model analysis for OS were not in concordance with the difference observed in the fixed effects model analysis. Administration of erlotinib only after chemotherapy obtained a higher objective response rate (ORR). Safety analyses indicated a slight increase in side-effects. The most common adverse events (AEs) were diarrhea and rash, which were usually manageable. There was no significant difference in treatment-related deaths. Erlotinib produced significant clinical benefits with acceptable toxicity as a maintenance strategy in patients with unresectable NSCLC, particularly when sequentially administered with chemotherapy. However, more well-designed randomized control trials (RCTs) are required to identify patients that may derive greater benefits from maintenance with erlotinib, and whether the use of erlotinib as maintenance therapy is more efficient than second-line treatment should also be investigated.
----------------------------------------------------
[25]
TÍTULO / TITLE: - Soft tissue metastases in lung cancer: a review of the literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Eur Rev Med Pharmacol Sci. 2012 Dec;16(14):1908-14.
AUTORES / AUTHORS: - Perisano C; Spinelli MS; Graci C; Scaramuzzo L; Marzetti E; Barone C; Fabbriciani C; Maccauro G
INSTITUCIÓN / INSTITUTION: - Department of Orthopaedics and Traumatology and Division of Medical Oncology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy. carloperisano@hotmail.it.
RESUMEN / SUMMARY: - <strong>Background:</strong> In lung cancer patients, metastases to soft tissues (STs), including skeletal muscle, subcutaneous tissue and skin, are rarely reported. Besides, lung cancer, primary carcinomas of the kidney and colon are the most commonly associated with ST metastases. <strong>Aim:</strong> To determine the prevalence, clinical-pathological features and treatment options of ST metastases originating from lung carcinoma. <strong>Materials and Methods:</strong> A literature search was performed using the following terms: lung cancer, ST metastasis, skeletal muscle metastasis, cutaneous metastasis, subcutaneous metastasis. <strong>Results:</strong> Autopsy series have detected STs metastases in 0.75-9% of patients who died from metastatic lung carcinoma. Pain and the presence of a palpable mass are the most frequent clinical features. The biopsy is recommended after MRI for diagnosis. Due to the rarity of ST metastases, the differential diagnosis must be posed especially with primary ST sarcomas. The type of treatment depends on the patient’s clinical status and prognosis, and includes observation, radiotherapy, chemotherapy and surgery. <strong>Conclusions:</strong> In lung cancer patients, ST metastases are rare, but not exceptional. Their presence should be suspected in the presence of a palpable mass either painful or asymptomatic. Radiological and histological examinations are required for the definite diagnosis. The choice of treatment should be based on considerations related to the stage of the primary tumor and the patient’s global health status.
----------------------------------------------------
[26]
TÍTULO / TITLE: - American Cancer Society lung cancer screening guidelines.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - CA Cancer J Clin. 2013 Jan 11. doi: 10.3322/caac.21172.
●● Enlace al texto completo (gratuito o de pago) 3322/caac.21172
AUTORES / AUTHORS: - Wender R; Fontham ET; Barrera E Jr; Colditz GA; Church TR; Ettinger DS; Etzioni R; Flowers CR; Scott Gazelle G; Kelsey DK; Lamonte SJ; Michaelson JS; Oeffinger KC; Shih YC; Sullivan DC; Travis W; Walter L; Wolf AM; Brawley OW; Smith RA
INSTITUCIÓN / INSTITUTION: - Chair and Alumni Professor, Department of Family and Community Medicine, Thomas Jefferson University Medical College, Philadelphia, PA.
RESUMEN / SUMMARY: - Answer questions and earn CME/CNE Findings from the National Cancer Institute’s National Lung Screening Trial established that lung cancer mortality in specific high-risk groups can be reduced by annual screening with low-dose computed tomography. These findings indicate that the adoption of lung cancer screening could save many lives. Based on the results of the National Lung Screening Trial, the American Cancer Society is issuing an initial guideline for lung cancer screening. This guideline recommends that clinicians with access to high-volume, high-quality lung cancer screening and treatment centers should initiate a discussion about screening with apparently healthy patients aged 55 years to 74 years who have at least a 30-pack-year smoking history and who currently smoke or have quit within the past 15 years. A process of informed and shared decision-making with a clinician related to the potential benefits, limitations, and harms associated with screening for lung cancer with low-dose computed tomography should occur before any decision is made to initiate lung cancer screening. Smoking cessation counseling remains a high priority for clinical attention in discussions with current smokers, who should be informed of their continuing risk of lung cancer. Screening should not be viewed as an alternative to smoking cessation. CA Cancer J Clin 2013. Esta es una cita bibliográfica que va por delante de la publicación en papel. La fecha indicada en la cita provista, NO corresponde con la fecha o la cita bibliográfica de la publicación en papel. La cita bibliográfica definitiva (con el volumen y su paginación) saldrá en 1 ó 2 meses a partir de la fecha de la emisión electrónica-online. *** This is a bibliographic record ahead of the paper publication. The given date in the bibliographic record does not correspond to the date or the bibliographic citation on the paper publication. The publisher will provide the final bibliographic citation (with the volume, and pagination) within 1 or 2 months from the date the record was published online. © 2013 American Cancer Society.
----------------------------------------------------
[27]
TÍTULO / TITLE: - Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Asian Pac J Cancer Prev. 2012;13(10):5177-82.
AUTORES / AUTHORS: - Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
INSTITUCIÓN / INSTITUTION: - Department of Oncology, Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai, China.
RESUMEN / SUMMARY: - PURPOSE: To compare the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitor monotherapy (EFGR-TKIs: gefitinib or erlotinib) with standard second-line chemotherapy (single agent docetaxel or pemetrexed) in previously treated advanced non-small-cell lung cancer (NSCLC). METHODS: We systematically searched for randomized clinical trials that compared EGFR-TKI monotherapy with standard second-line chemotherapy in previously treated advanced NSCLC. The end points were overall survival (OS), progression-free survival (PFS), overall response rate (ORR), 1-year survival rate (1-year SR) and grade 3 or 4 toxicities. The pooled hazard ratio (HR) or risk ratio (RR), with their corresponding 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials. RESULTS: Eight randomized controlled trials (totally 3218 patients) were eligible. Our meta-analysis results showed that EGFR-TKIs were comparable to standard second-line chemotherapy for advanced NSCLC in terms of overall survival (HR 1.00, 95%CI 0.92-1.10; p=0.943), progression-free survival (HR 0.90, 95%CI 0.75-1.08, P=0.258) and 1-year-survival rate (RR 0.97, 95%CI 0.87-1.08, P=0.619), and the overall response rate was higher in patients who receiving EGFR-TKIs(RR 1.50, 95%CI 1.22-1.83, P=0.000). Sub-group analysis demonstrated that EGFR-TKI monotherapy significantly improved PFS (HR 0.73, 95%CI: 0.55-0.97, p=0.03) and ORR (RR 1.96, 95%CI: 1.46-2.63, p=0.000) in East Asian patients, but it did not translate into increase in OS and 1-year SR. Furthermore, there were fewer incidences of grade 3 or 4 neutropenia, febrile neutropenia and neurotoxicity in EGFR-TKI monotherapy group, excluding grade 3 or 4 rash. CONCLUSION: Both interventions had comparable efficacy as second-line treatments for patients with advanced NSCLC, and EGFR-TKI monotherapy was associated with less toxicity and better tolerability. Moreover, our data also demonstrated that EGFR- TKI monotherapy tended to be more effective in East Asian patients in terms of PFS and ORR compared with standard second-line chemotherapy. These results should help inform decisions about patient management and design of future trials.
----------------------------------------------------
[28]
TÍTULO / TITLE: - Synchronous primary lung cancer. Critical review of diagnostic criteria.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Ann Ital Chir. 2012 Nov 15. pii: S0003469X1201799X.
AUTORES / AUTHORS: - Scialpi M; Franzini C; Piscioli I; Barberini F; Pusiol T; Rondelli F; Nicolanti V; Rulli A; Izzo P; Merlin G; Forcione AR; Pugliese F; Di Cello P; Paliotta A; Izzo L
RESUMEN / SUMMARY: - QUESTION OF THE STUDY: Synchronous primary lung cancers (SPLCs) may pose a radiologic-pathologic and therapeutic dilemma in according to recent WHO classification. PATIENTS AND METHODS: Two cases of surgically treated SPLCs are reported. RESULTS: In the first case two nodules were detected by Computed Tomography (CT) in the upper right lobe. The patient underwent lobectomy and histological diagnosis was adenocarcinoma and squamous cell carcinoma. The second patient presented at CT one nodule in the upper left lobe and another nodule in the upper right lobe. Sternotomic access was chosen for bilateral removal of the lesions. The diagnosis was sarcomatoid carcinoma and large cell neuroendocrine adenocarcinoma. DISCUSSION: The criteria of Martini and Melamed are inadequate for the diagnosis of SPLCs. The use of TTF-1 (thyroid transcription factor-1) is necessary to establish the diagnosis of SPLC in patients with adenocarcinoma of other sites. Bronchioloalveolar carcinomas must be excluded because of their multicentricity. When histology of two tumors found in the same lobe is identical and histotype is adenocarcinoma, large cell carcinoma or sarcomatoid carcinoma, the diagnosis of SPLCs must be excluded and those lesions must be considered as metastatic disease. The prognosis and treatment of SPLCs are discussed after critical review of the literature. KEY WORDS: Large cell neuroendocrine cancers, Sarcomatoid carcinoma, Synchronous primary lung cancers.
----------------------------------------------------
[29]
TÍTULO / TITLE: - Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: A case report and review of the literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Oncol Lett. 2012 Dec;4(6):1341-1343. Epub 2012 Sep 10.
●● Enlace al texto completo (gratuito o de pago) 3892/ol.2012.904
AUTORES / AUTHORS: - Zheng Y; Fang W; Xu N
INSTITUCIÓN / INSTITUTION: - Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R. China.
RESUMEN / SUMMARY: - Icotinib is a new oral epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI). The most frequent side-effects of icotinib include rash and diarrhea. Hand-foot syndrome (HFS) induced by EGFR-TKI is rare. The present study describes, for the first time, HFS induced by high-dose icotinib in a 65-year old female with metastatic lung adenocarcinoma. The patient developed HFS during the first week of icotinib treatment with characteristic clinical presentation. HFS regressed after icotinib dose-reduction was initiated. HFS may occur with icotinib, especially when administered in high doses.
----------------------------------------------------
[30]
TÍTULO / TITLE: - A literature-based systematic HuGE review and meta-analysis show that CASP gene family polymorphisms are associated with risk of lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Genet Mol Res. 2013 Jan 4;12(AOP).
●● Enlace al texto completo (gratuito o de pago) 4238/2013.January.4.22
AUTORES / AUTHORS: - Zhang ZY; Xuan Y; Jin XY; Tian X; Wu R
INSTITUCIÓN / INSTITUTION: - Department of Oncology, Shengjing Affiliated Hospital of China Medical University, Shenyang, Liaoning, China cmuzhangzy@163.com.
RESUMEN / SUMMARY: - The caspase (CASP) gene family is known to be involved in apoptosis, cytokine maturation, cell growth and differentiation. A large number of single nucleotide polymorphisms (SNPs) in the CASP gene family have been increasingly recognized as important regulators in the development of lung cancer. However, this specific association is still controversial. In this Human Genome Epidemiology review and meta-analysis, we summarized the available evidence associating lung cancer with the CASP gene family. Seven studies, which included 1155 lung cancer cases and 1120 healthy controls, met the inclusion criteria and were included in our meta-analysis. In seven studies, 19 different SNPs have been studied in seven CASP genes, including CASP-1, -2, -5, -7, -8, -9, and -10. Meta-analysis results showed positive associations between heterozygote (A/G) of rs507879 in the CASP-5 gene, the T allele of rs12415607 in the CASP-7 gene, and the T allele and T carrier (C/T+T/T) of rs4645981 in the CASP-9 gene with lung cancer susceptibility [odds ratio (OR) = 1.83, 95% confidence interval (95%CI) = 1.07-3.12, P = 0.03; OR = 1.18, 95%CI = 1.02-1.37, P = 0.03; OR = 1.43, 95%CI = 1.12-1.81, P = 0.004; OR = 1.46, 95%CI = 1.10- 1.93, P = 0.009; respectively]. However, we found that homozygote (G/G) of rs2227310 in the CASP-7 gene, del allele, heterozygote (ins/ del) and del carrier (ins/del + del/del) of rs3834129 in CASP-8 could be protective factors for lung cancer (OR = 0.17, 95%CI = 0.14-0.21, P = 0.0003; OR = 0.83, 95%CI = 0.72-0.97, P = 0.02; OR = 0.74, 95%CI = 0.64-0.85, P < 0.0001; OR = 0.81, 95%CI = 0.71-0.93, P = 0.002; respectively). In conclusion, based on this meta-analysis, we suggest that SNPs in CASP-5, CASP-7, CASP-8, and CASP-9 are associated with susceptibility to lung cancer.
----------------------------------------------------
[31]
TÍTULO / TITLE: - Concordance between thoracic multidisciplinary meeting recommendations for radiation therapy and actual treatment for lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Med Imaging Radiat Oncol. 2012 Dec;56(6):696-702. doi: 10.1111/j.1754-9485.2012.02460.x. Epub 2012 Oct 17.
●● Enlace al texto completo (gratuito o de pago) 1111/j.1754-9485.2012.02460.x
AUTORES / AUTHORS: - Loh J; Stevens G; Stevens W; Kolbe J
INSTITUCIÓN / INSTITUTION: - Department of Radiation Oncology, Auckland Hospital, Auckland, New Zealand. jyuin@yahoo.com
RESUMEN / SUMMARY: - INTRODUCTION: There is limited evidence whether decisions of Thoracic Multidisciplinary Meetings (TMDMs) are reflected in the treatment lung cancer patients actually receive. Aims were to determine concordance between TMDM recommendations for radiotherapy (RT) and actual RT administered and to compare cases that received RT that were referred or not referred from TMDMs. METHOD: A retrospective review of demographic and clinical data for all lung cancer cases within the Auckland-Northland region referred for RT from TMDMs (January-June 2009) and all cases that received RT but were not referred from TMDMs (January-August 2009). RESULTS: Of 110 cases referred for RT from TMDMs, 86 (78%) were offered RT (76 with the same treatment intent) and 78 (71%) received RT. Ten (9%) cases were deemed unsuitable for RT; 7 (6%) deteriorated; 4 (4%) declined or did not attend; 3% other. Fifty-one other cases received RT without TMDM presentation. Cases with remote domicile or recurrent disease were significantly less likely to have been presented at TMDMs. TMDM presentation did not significantly increase transit time to RT. The proportion of RT cases referred from TMDMs had increased substantially since 2004. CONCLUSION: The concordance between TMDM recommendations for RT and both the RT administered and the intent of treatment suggests a useful role for TMDMs. Concordance could be increased by improving RT timeliness and improved education of other disciplines and patients regarding the role of RT. Strategies to increase presentation at TMDM include attention to geographically isolated groups.
----------------------------------------------------
[32]
TÍTULO / TITLE: - Clinical significance and role of lymphatic vessel invasion as a major prognostic implication in non-small cell lung cancer: a meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - PLoS One. 2012;7(12):e52704. doi: 10.1371/journal.pone.0052704. Epub 2012 Dec 20.
●● Enlace al texto completo (gratuito o de pago) 1371/journal.pone.0052704
AUTORES / AUTHORS: - Wang J; Wang B; Zhao W; Guo Y; Chen H; Chu H; Liang X; Bi J
INSTITUCIÓN / INSTITUTION: - Department of Oncology, General Hospital, Jinan Command of the People’s Liberation Army, Jinan, China.
RESUMEN / SUMMARY: - BACKGROUND: Lymphatic vessel invasion (LVI) exerts an important process in the progression and local spread of cancer cells. However, LVI as a prognostic factor for survival in non-small cell lung cancer (NSCLC) remains controversial. METHODOLOGY/PRINCIPAL FINDINGS: A meta-analysis of published studies from PubMed and EMBASE electronic databases was performed to quantity the effects of LVI on both relapse-free survival and overall survival for patients with NSCLC. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to assess the strength of these effects. This meta-analysis included 18,442 NSCLC patients from 53 eligible studies. LVI appeared in 32.1% (median; range, 2.8% to 70.9%) of tumor samples. In all, patients with LVI were 2.48 times more likely to relapse by univariate analysis (95% CI: 1.92-3.22) and 1.73 times by multivariate analysis (95% CI: 1.24-2.41) compared with those without LVI. For the analyses of LVI and overall survival, the pooled HR estimate was 1.97 (95% CI: 1.75-2.21) by univariate analysis and 1.59 (95% CI: 1.41-1.79) by multivariate analysis. Multivariate analysis showed a risk was 91% higher for recurrence (HR = 1.91, 95% CI: 1.14-2.91) and 70% higher for mortality (HR = 1.70, 95% CI: 1.38-2.10) in LVI-positive I stage patients compared with LVI-negative I stage patients. Subgroup analyses showed similar significant adjusted risks for recurrence and death in adenocarcinomas, and a significant adjusted risk for death in studies that utilized elastic staining with or without immunohistochemistry in defining LVI. CONCLUSIONS/SIGNIFICANCE: The present study indicates that LVI appears to be an independent poor prognosticator in surgically managed NSCLC. NSCLC patients with LVI would require a more aggressive treatment strategy after surgery. However, large, well-designed prospective studies with clinically relevant modeling and standard methodology to assess LVI are required to address some of these important issues.
----------------------------------------------------
[33]
TÍTULO / TITLE: - Survival Prediction and Treatment Recommendation with Bayesian Techniques in Lung Cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - AMIA Annu Symp Proc. 2012;2012:838-847. Epub 2012 Nov 3.
AUTORES / AUTHORS: - Sesen MB; Kadir T; Alcantara RB; Fox J; Brady M Sir
INSTITUCIÓN / INSTITUTION: - University of Oxford, UK.
RESUMEN / SUMMARY: - In this paper, we investigate a number of Bayesian techniques for predicting 1-year- survival and making treatment selection recommendations for lung cancer. We have carried out two sets of experiments on the English Lung Cancer Dataset. For 1-year-survival prediction, the Naive Bayes (NB) algorithm achieved an area under the curve value of 81%, outperforming the Bayesian Networks learned by the M(3) and K2 structure learning algorithms. For treatment recommendation, the Bayesian Network, whose structure was learned by the MC(3) algorithm, has marginally outperformed NB, based on producing concordant results with the recorded treatments in the dataset. We observed that in cases where the classifier recommendations were discordant with the recorded treatments, the 1-year-survival rate decreased by 15%. We also observed that discordance between the classifier and the dataset was more dominant in cases where the recorded treatment was non-curative or was not frequently encountered in the dataset.
----------------------------------------------------
[34]
TÍTULO / TITLE: - Menstrual Factors, Reproductive Factors and Lung Cancer Risk: A Meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Zhongguo Fei Ai Za Zhi. 2012 Dec 20;15(12):701-19. doi: 10.3779/j.issn.1009-3419.2012.12.04.
●● Enlace al texto completo (gratuito o de pago) 3779/j.issn.1009-3419.2012.12.04
AUTORES / AUTHORS: - Zhang Y; Yin Z; Shen L; Wan Y; Zhou B
INSTITUCIÓN / INSTITUTION: - Department of Epidemiology, School of Public Health, China Medical University, Shenyang 110001, China;Key Laboratory of Cancer Etiology and Intervention, Liaoning University, Shenyang 110036, China;China Medical University Center For Evidence-based Medicine, Shenyang 110001, China.
RESUMEN / SUMMARY: - BACKGROUND: Epidemiological studies have suggested that menstrual and reproductive factors may influence lung cancer risk, but the results are controversial. We therefore carried out a meta-analysis aiming to examine the associations of lung cancer in women with menstrual and reproductive factors. METHODS: Relevant studies were searched from PubMed database, CNKI, WANFANG DATA and VIP INFORMATION up to January 2012, with no language restrictions. References listed from selected papers were also reviewed. We included studies that reported the estimates of relative risks (RRs) with 95% confidence intervals (CIs) for the association between menstrual and reproductive factors and lung cancer risk. The pooled RRs were calculated after the heterogeneity test with the software Stata 11, and publication bias and sensitivity were evaluated at the same time. RESULTS: Twenty-five articles, representing 24 independent studies, were included in this meta-analysis. Older age at menarche in North America women (RR=0.83; 95%CI: 0.73-0.94) was associated with a significant decreased risk of lung cancer. Longer length of menstrual cycle was also associated with decreased lung cancer risk (RR=0.72; 95%CI: 0.57-0.90). Other exposures were not significantly associated. CONCLUSIONS: Our analysis provides evidence of the hypothesis that female sex hormones influence the risk of lung cancer in women, yet additional studies are warranted to extend this finding and to clarify the underlying mechanisms.
----------------------------------------------------
[35]
TÍTULO / TITLE: - A systematic review of supportive care needs of people living with lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Eur J Oncol Nurs. 2012 Dec 13. pii: S1462-3889(12)00116-0. doi: 10.1016/j.ejon.2012.10.013.
●● Enlace al texto completo (gratuito o de pago) 1016/j.ejon.2012.10.013
AUTORES / AUTHORS: - Maguire R; Papadopoulou C; Kotronoulas G; Simpson MF; McPhelim J; Irvine L
INSTITUCIÓN / INSTITUTION: - School of Nursing & Midwifery, University of Dundee, 11 Airlie Place, Dundee DD1 4HJ, UK. Electronic address: r.z.maguire@dundee.ac.uk.
RESUMEN / SUMMARY: - BACKGROUND AND PURPOSE: Supportive care for people living with a diagnosis of lung cancer is paramount. The purpose of this systematic review was to determine the supportive care needs of people with lung cancer, and explore trends and gaps in the assessment of these needs emerging from this literature. METHODS: Through use of a wide range “free text” terms, a systematic search of five electronic databases (Medline, CINAHL, EMBASE, PsychINFO and BNI) was carried out for the period between January 2000 and September 2012. Two validated scoring systems were used to appraise eligible studies for methodological quality and level of evidence. RESULTS: Based on pre-specified selection criteria, 59 articles (25 of quantitative methodology; 34 of qualitative methodology) reporting on 53 studies were retrieved and considered for further analysis. Overall, studies were of acceptable methodological quality. A wide spectrum of health care needs was evident among people with lung cancer. These needs were classified into nine domains: physical; daily living; psychological/emotional; spiritual/existential; informational; practical; patient-clinician communication; social and family-related; and cognitive. Daily living, practical, and cognitive needs were given less attention in this literature. CONCLUSIONS: People with lung cancer have a complex array of supportive care needs that impact on various life aspects. Yet, our knowledge still remains fragmentary. Embarking on new longitudinal exploratory studies and well-designed clinical trials is therefore strongly encouraged. The use of patient reported outcome measures as a clinical intervention tool may be viewed as a means of identifying and managing unmet needs in this patient population.
----------------------------------------------------
[36]
TÍTULO / TITLE: - Maintenance Therapy for NSCLC: Consensus and Controversy.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Chin J Cancer Res. 2011 Dec;23(4):254-8. doi: 10.1007/s11670-011-0254-5.
●● Enlace al texto completo (gratuito o de pago) 1007/s11670-011-0254-5
AUTORES / AUTHORS: - Lu S; Yu YF
INSTITUCIÓN / INSTITUTION: - Shanghai Lung Cancer Center, Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200030, China.
RESUMEN / SUMMARY: - Nowadays, advanced non-small cell lung cancer (NSCLC) is still an incurable disease. However, recent researches on maintenance therapy have led to considerable progress. Recently, pemetrexed and erlotinib have been approved for maintenance chemotherapy by both the U.S. Food and Drug Administration and European Medicines Agency. However, there are not adequate data to support the maintenance therapy as the standard treatment for advanced NSCLC and there has been no conclusive predictor of who will get benefit from maintenance chemotherapy and what type of maintenance, continuation or switch, is preferred. This article reviews the main studies on maintenance therapy of advanced NSCLC and discusses the results available to date.
----------------------------------------------------
[37]
TÍTULO / TITLE: - Malignant peritoneal mesothelioma (MPM) who responded to rechallenge with cisplatin and pemetrexed with current literature review.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - British Medical J (BMJ). Acceso gratuito al texto completo.
●● Enlace a la Editora de la Revista http://bmj.com/search.dtl
●● Cita: British Medical J. (BMJ): <> Case Rep. 2013 Jan 3;2013. pii: bcr2012007786. doi: 10.1136/bcr-2012-007786.
●● Enlace al texto completo (gratuito o de pago) 1136/bcr-2012-007786
AUTORES / AUTHORS: - Gilani SN; Gridley R; Searle G; Jegannathen A
INSTITUCIÓN / INSTITUTION: - Department of Clinical Oncology, University Hospital of North Staffordshire, Stoke On Trent, Staffordshire, UK.
RESUMEN / SUMMARY: - Peritoneal mesothelioma is an aggressive malignancy which is indeed very rare. Due to rarity, experience among many physicians surrounding the treatment of peritoneal mesothelioma is limited. Recently, we have received a patient who was initially treated palliatively with a combination of pemetrexd and cisplatin showing good response. On progression of his disease, he was again treated with the same drugs. This is not the strategy commonly used. We consider rechallenging cisplatin and pemetrexd to such patients who respond for the first time.
----------------------------------------------------
[38]
TÍTULO / TITLE: - Sleeve lobectomy versus pneumonectomy for non-small cell lung cancer: a meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - World J Surg Oncol. 2012 Dec 11;10:265. doi: 10.1186/1477-7819-10-265.
●● Enlace al texto completo (gratuito o de pago) 1186/1477-7819-10-265
AUTORES / AUTHORS: - Shi W; Zhang W; Sun H; Shao Y
INSTITUCIÓN / INSTITUTION: - Department of Cardio-Thoracic Surgery, the first Affiliated Hospital of Nanjing Medical University, 300# guangzhou road, Nanjing, 210029, China. yongfeng_shao@163.com.
RESUMEN / SUMMARY: - ABSTRACT: AIM: It is controversial that whether sleeve lobectomy (SL) should be promoted more worthy than pneumonectomy (PN) in suitable patients. METHODS: We searched all studies that had been published in English from PUBMED and Embase which compared the short-term and long-term outcomes of SL and pneumonectomy (PN) in patients with non-small cell lung cancer (NSCLC). RESULTS: Nineteen studies met our criteria with a combined total of 3878 subjects, of which 1316 (33.9%) underwent SL and 2562 (66.1%) underwent PN. The odds ratio was 0.50 (95% CI: 0.34-0.72) for postoperative mortality, 1.17 (95% CI: 0.82-1.67) for postoperative complications, 0.78 (95% CI: 0.47-1.29) for locoregional recurrences. The risk difference for 1-, 3-, 5- year was 0.11 (95% CI: 0.07-0.14), 0.15 (95% CI: 0.06-0.24), 0.15 (95% CI: 0.09-0.20),respectively. The pooled hazard ratio was 0.63 (95% CI: 0.56-0.71) in favor of SL group. CONCLUSION: SL is more worthy to be done than PN in suitable patients with less mortality and better long-term survival.
----------------------------------------------------
[39]
TÍTULO / TITLE: - Pulmonary hamartoma: Cytological study of a case and literature review.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Cytol. 2012 Oct;29(4):261-3. doi: 10.4103/0970-9371.103948.
●● Enlace al texto completo (gratuito o de pago) 4103/0970-9371.103948
AUTORES / AUTHORS: - Umashankar T; Devadas AK; Ravichandra G; Yaranal PJ
INSTITUCIÓN / INSTITUTION: - Department of Pathology, Yenepoya Medical College, Mangalore, Karnataka, India.
RESUMEN / SUMMARY: - Pulmonary hamartomas are the most common but rare benign tumor-like lesions of the lung arising from the embryonic rest. They are more common in males and in aged. Majority are asymptomatic and seen as coin lesions with popcorn calcification in the chest radiograph. Fine needle aspiration cytology (FNAC) helps to diagnose and distinguish them from the cancerous lesions of the lung. The cytological material is characterized by fibromyxoid stroma, cartilage, bronchial cells, adipose tissue and bone. Bronchial cells with reactive atypia may be a source of false-positive result. Symptomatic cases need surgical intervention such as enucleation or segmental resection. We report a case of a 74-year-old male who had a lung mass that did not progress over 4-year on chest radiograph. The CT-guided FNAC smears showed benign bronchial epithelial cells, fibro-myxoid spindle cell stroma and fat spaces that aided the diagnosis of pulmonary hamartoma avoiding surgical intervention.
----------------------------------------------------
[40]
TÍTULO / TITLE: - Is 68Ga-DOTATATE the answer in lung carcinoid? : Case report and review of literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Lung India. 2012 Oct;29(4):378-80. doi: 10.4103/0970-2113.102839.
●● Enlace al texto completo (gratuito o de pago) 4103/0970-2113.102839
AUTORES / AUTHORS: - Bhoil A; Mittal BR; Gayana S; Kashyap R; Bhattacharya A; Singh N
INSTITUCIÓN / INSTITUTION: - Department of Nuclear Medicine and PET, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
RESUMEN / SUMMARY: - Carcinoid tumors are rich in somatostatin receptors and show high uptake of radiotracer on octreotide scintigraphy. 68Ga-DOTATATE could be of great help at initial staging and during follow-up of these patients. We describe a patient with avid 68Ga-DOTATATE and poor F18-FDG uptake.
----------------------------------------------------
[41]
TÍTULO / TITLE: - Benign cystic mesothelioma of the peritoneum: a rare case and review of the literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Case Rep Oncol. 2012 Sep;5(3):667-70. doi: 10.1159/000346187. Epub 2012 Dec 19.
●● Enlace al texto completo (gratuito o de pago) 1159/000346187
AUTORES / AUTHORS: - Khuri S; Gilshtein H; Abboud W; Assalia A; Kluger Y
INSTITUCIÓN / INSTITUTION: - Department of General Surgery, Rambam Health Care Center, Haifa, Israel.
RESUMEN / SUMMARY: - A 19-year-old male presented with right lower quadrant pain. Imaging studies revealed a cystic peritoneal mass. At surgery, a large peritoneal mass was excised. The pathology report revealed a benign cystic mesothelioma, and a right hemicolectomy with cytoreductive surgery was completed.
----------------------------------------------------
[42]
TÍTULO / TITLE: - Recent advances in video-assisted thoracoscopic surgery for lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Asian J Endosc Surg. 2013 Feb;6(1):9-13. doi: 10.1111/ases.12013. Epub 2012 Dec 21.
●● Enlace al texto completo (gratuito o de pago) 1111/ases.12013
AUTORES / AUTHORS: - Ikeda N; Saji H; Hagiwara M; Ohira T; Usuda J; Kajiwara N
INSTITUCIÓN / INSTITUTION: - Department of Surgery, Tokyo Medical University, Tokyo, Japan.
RESUMEN / SUMMARY: - As a result of increased use of CT in both screening and daily practice, the number of early lung cancers has increased enormously. Surgeons pursue both curativity and reduced invasiveness in treating patients with early stage lung cancer; therefore, minimally invasive operations, such as video-assisted thoracoscopic surgery (VATS) lobectomy are now being routinely performed. Most previous reports have shown that there is no difference in mortality and local recurrence between open surgery and VATS in stage I patients. However, surgeons’ improved technical experience and patients’ demands could soon make VATS lobectomy the operative method of choice for early stage lung cancer. Moreover, the indications for VATS are expanding to encompass complex procedures such as segmentectomy or sleeve resection. Training and dissemination of the technique and the monitoring of outcomes are necessary.
----------------------------------------------------
[43]
TÍTULO / TITLE: - Saudi Lung Cancer Guidelines update 2012.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Infect Public Health. 2012 Dec;5 Suppl 1:S11-3. doi: 10.1016/j.jiph.2012.09.012. Epub 2012 Nov 15.
●● Enlace al texto completo (gratuito o de pago) 1016/j.jiph.2012.09.012
AUTORES / AUTHORS: - Jazieh AR
INSTITUCIÓN / INSTITUTION: - Department of Oncology (Mail Code 1777), King Abdulaziz Medical, P.O. Box 22490, Riyadh 11426, Saudi Arabia. Electronic address: jazieha@ngha.med.sa.
----------------------------------------------------
[44]
TÍTULO / TITLE: - The lung cancer management guidelines 2012.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Infect Public Health. 2012 Dec;5 Suppl 1:S4-S10. doi: 10.1016/j.jiph.2012.09.011. Epub 2012 Nov 6.
●● Enlace al texto completo (gratuito o de pago) 1016/j.jiph.2012.09.011
AUTORES / AUTHORS: - Jazieh AR
INSTITUCIÓN / INSTITUTION: - Department of Oncology (Mail code 1777), King Abdulaziz Medical, P.O. Box 22490, Riyadh 11426, Saudi Arabia. Electronic address: jazieha@ngha.med.sa.
----------------------------------------------------
[45]
TÍTULO / TITLE: - Guidelines for the role of FDG-PET/CT in lung cancer management.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Infect Public Health. 2012 Dec;5 Suppl 1:S35-40. doi: 10.1016/j.jiph.2012.09.003. Epub 2012 Nov 6.
●● Enlace al texto completo (gratuito o de pago) 1016/j.jiph.2012.09.003
AUTORES / AUTHORS: - Al-Jahdali H; Khan AN; Loutfi S; Al-Harbi AS
INSTITUCIÓN / INSTITUTION: - Pulmonary Division, Department of Medicine, King Saud University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
RESUMEN / SUMMARY: - Fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET) and PET/computed tomography (FDG-PET/CT) is regarded as a standard of care in the management of non-small-cell lung carcinoma (NSCLC) and is a useful adjunct in the characterization of indeterminate solitary lung nodules (SLN), and pre-treatment staging of NSCLC, notably mediastinal nodal staging and detection of remote metastases. FDG-PET/CT has the ability to assess locoregional lymph node spread more precisely than CT, to detect metastatic lesions that would have been missed on conventional imaging or are located in difficult areas, and to help in the differentiation of lesions that are equivocal after conventional imaging. Increasingly FDG-PET/CT is employed in radiotherapy planning, prediction of prognosis in terms of tumor response to neo-adjuvant, radiation and chemotherapy treatment. Evidence is accumulating of usefulness of PET/CT in small cell lung cancer.
----------------------------------------------------
[46]
TÍTULO / TITLE: - Guidelines for multimodality radiological staging of lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Infect Public Health. 2012 Dec;5 Suppl 1:S14-21. doi: 10.1016/j.jiph.2012.09.009. Epub 2012 Nov 6.
●● Enlace al texto completo (gratuito o de pago) 1016/j.jiph.2012.09.009
AUTORES / AUTHORS: - Loutfi S; Khankan A; Ghanim SA
INSTITUCIÓN / INSTITUTION: - Medical Imaging Department, King Abdulaziz Medical City, P.O. Box: 22490, Riyadh, Saudi Arabia.
RESUMEN / SUMMARY: - Lung cancer is among the most common type of cancers and is a leading cause of cancer-related deaths with smoking representing the leading risk factor. It is classified into non-small cell lung cancer (NSCLC) representing 70-80% of cases and small cell lung cancer (SCLC) which has neuroendocrine properties with poor outcome. Staging of NSCLC is based on the TNM classification system while SCLC was usually classified into limited and extensive disease, though the use of TNM staging system for SCLC is recommended. Imaging studies are used to determine the pre-operative staging of lung cancer. Accurate radiological staging is essential to determine tumor resectability as well as to avoid futile surgeries and to assess patient’s outcome. Moreover, radiological examinations are used for the evaluation of tumor response to treatment. This manuscript will review the utilization of imaging studies in the management of lung cancer based on the most recent guidelines by the National Comprehensive Cancer Network (NCCN).
----------------------------------------------------